ArticleBMC gastroenterology2012
Comparative analysis of inflamed and non-inflamed colon biopsies reveals strong proteomic inflammation profile in patients with ulcerative colitis.
Article in BMC gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 52 citations in OpenAlex.
- The Use of Tissue Concentrations of Biological and Small-Molecule Therapies in Clinical Studies of Inflammatory Bowel Diseases.Pharmaceutics · 2024Review
- Proteomic Differences in Colonic Epithelial Cells in Ulcerative Colitis Have an Epigenetic Basis.Gastro hep advances · 2024Article
- Longitudinal gut microbiome analyses and blooms of pathogenic strains during lupus disease flares.Annals of the rheumatic diseases · 2023Observational
- A Current State of Proteomics in Adult and Pediatric Inflammatory Bowel Diseases: A Systematic Search and Review.International journal of molecular sciences · 2023Review
- Loss of Peroxiredoxin IV Protects Mice from Azoxymethane/Dextran Sulfate Sodium-Induced Colorectal Cancer Development.Antioxidants (Basel, Switzerland) · 2023Article
- Essential Roles of Peroxiredoxin IV in Inflammation and Cancer.Molecules (Basel, Switzerland) · 2022Review
- Proteomic characterisations of ulcerative colitis endoscopic biopsies associate with clinically relevant histological measurements of disease severity.Journal of clinical pathology · 2022Article
- Actin cytoskeleton dynamics during mucosal inflammation: a view from broken epithelial barriers.Current opinion in physiology · 2021Article
- Assessment of the usefulness of imaging studies and biomarkers in the activity of Crohn's disease.Przeglad gastroenterologiczny · 2021Article
- Oxidative Stress Markers in Inflammatory Bowel Diseases: Systematic Review.Diagnostics (Basel, Switzerland) · 2020Review
- Review
- Proteomic insights on the metabolism in inflammatory bowel disease.World journal of gastroenterology · 2020Review
- Fecal Serine Protease Profiling in Inflammatory Bowel Diseases.Frontiers in cellular and infection microbiology · 2020Article
- Proteomics-based functional studies reveal that galectin-3 plays a protective role in the pathogenesis of intestinal Behçet's disease.Scientific reports · 2019Article
- Close association between abnormal expressed enzymes of energy metabolism and diarrhea-predominant irritable bowel syndrome.Chinese medical journal · 2019Article
- Application of Proteomics to Inflammatory Bowel Disease Research: Current Status and Future Perspectives.Gastroenterology research and practice · 2019Review
- Ulcerative colitis: functional analysis of the in-depth proteome.Clinical proteomics · 2019Article
- Functional Proteomic Profiling of Secreted Serine Proteases in Health and Inflammatory Bowel Disease.Scientific reports · 2018Article
- Costus root granules improve ulcerative colitis through regulation of TGF-β mediation of the PI3K/AKT signaling pathway.Experimental and therapeutic medicine · 2018Article
- A novel Ruminococcus gnavus clade enriched in inflammatory bowel disease patients.Genome medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate diagnostic and monitoring tools for ulcerative colitis (UC) are missing. Our aim was to describe the proteomic profile of UC and search for markers associated with disease exacerbation. Therefore, we aimed to characterize specific proteins associated with inflamed colon mucosa from patients with acute UC using mass spectrometry-based proteomic analysis.
methodsBiopsies were sampled from rectum, sigmoid colon and left colonic flexure from twenty patients with active proctosigmoiditis and from four healthy controls for proteomics and histology. Proteomic profiles of whole colonic biopsies were characterized using 2D-gel electrophoresis, and peptide mass fingerprinting using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) was applied for identification of differently expressed protein spots.
resultsA total of 597 spots were annotated by image analysis and 222 of these had a statistically different protein level between inflamed and non-inflamed tissue in the patient group. Principal component analysis clearly grouped non-inflamed samples separately from the inflamed samples indicating that the proteomic signature of colon mucosa with acute UC is strong. Totally, 43 individual protein spots were identified, including proteins involved in energy metabolism (triosephosphate isomerase, glycerol-3-phosphate-dehydrogenase, alpha enolase and L-lactate dehydrogenase B-chain) and in oxidative stress (superoxide dismutase, thioredoxins and selenium binding protein).
conclusionsA distinct proteomic profile of inflamed tissue in UC patients was found. Specific proteins involved in energy metabolism and oxidative stress were identified as potential candidate markers for UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.